Fig. 3: Inhibition of ZIKV infection by antibody to ITGB4.
From: ITGB4/CD104 mediates zika virus attachment and infection
a A surface plasmon resonance assay (SPR) characterizing the binding between ITGB4/ITGA6 and 13H10 antibody. The 13H10 antibody were immobilized on the chip at about 300 response units. Concentrations of ITGB4/ITGA6 was used to flow over the chip surface. 13H10 was ITGB4 specific antibody. b Cells were treated with various concentrations of 13H10 or isotype antibody for 1 h and infected with ZIKV with MOI = 0.05. Virus titers were determined by plaque assay on Vero cells at 48 h after infection. The values in the graph represent the mean ± SD of n = 3 independent experiments. ***P = 0.0082 (Vero), ****p < 0.0001 (Vero), **P = 0.0052 (A549), ***p = 0.0005 (A549), ***P = 0.0002 (Hun7), ****p < 0.0001 (Hun7), ****p < 0.0001 (MK2), **P = 0.0046 (hNPCs), ***P = 0.0002 (hNPCs), two-sided, multiple comparisons by One-way ANOVA test. c Cells were preincubated with isotype antibody or indicated concentrations of 13H10 antibody for 1 h and then challenged with ZIKV with MOI = 10 at 4 °C for 1 h. Cells were washed, and total RNA was extracted. ZIKV RNA was quantified by RT-PCR. The results were expressed as ZIKV RNA levels relative to the expression of the GAPDH internal control gene. The data were expressed as Mean ± SD of three independent experiments. ****P < 0.0001 (Hun7, top), ***P = 0.0001 (Hun7, middle), **P = 0.0042 (Hun7, bottom), ***P = 0.0002 (Vero, top), **P = 0.0019 (Vero, middle), *P = 0.0192 (Vero, bottom), ****P < 0.0001 (A549, top), ****P < 0.0001 (A549, middle), **P = 0.0029 (A549, bottom), ***P = 0.0002 (MK2, top), **P = 0.0025 (MK2, middle), *P = 0.0216 (MK2, bottom), ***P = 0.0003 (hNPCs, top), **P = 0.0060 (hNPCs, middle), *P = 0.0169 (hNPCs, bottom), two-sided, multiple comparisons by One-way ANOVA test.
